Navigation Links
Convoy Therapeutics Appoints Clinical Advisory Board
Date:11/5/2013

Oro Valley, Arizona (PRWEB) November 05, 2013

Convoy Therapeutics, a late pre-approval stage dermatology company, announced the creation of its clinical advisory board (CAB) today. The Convoy CAB is composed of six distinguished experts whose mission will be to advise Convoy Therapeutics on the development of robust clinical strategies and effective approaches to support commercialization for Convoy’s pipeline of new products powered by Convoy’s patented Skin Penetrating And Cell Entering peptide dermal delivery technology, “SPACE”.

Convoy’s President and CEO, John Muraski, Ph.D., said, “The creation of our Clinical Advisory Board is an essential step for Convoy. Establishing a robust clinical strategy with the advice of these experts is critical to link our technology and innovation with solutions for unmet medical needs and commercialization optimization.”

Composition of the Clinical Advisory Board

Dr. Alan Menter
Dr. Menter is Chairman of the Division of Dermatology at Baylor University Medical Center and head of Psoriasis research at the Baylor Research Institute. He is also Past President of International Psoriasis Council. After obtaining his medical degree from the University of Witwatersrand in Johannesburg and residency in dermatology at the University of Pretoria in South Africa, Dr. Menter completed fellowships at Guy’s Hospital and St. John’s Hospital for Diseases of the Skin, in London. Dr. Menter then came to the United States and completed a fellowship in dermatology at Southwestern Medical School in Dallas and was Board Certified in dermatology in 1977.

Dr. Mark Lebwohl
Dr. Lebwohl is a professor and chairman of the Department of Dermatology at The Mount Sinai School of Medicine. He is also Chairman of the Medical Board of the National Psoriasis Foundation and a current member of the Board of Directors of the American Academy of Dermatology. Dr. Lebwohl graduated from Harvard Medical School in 1978 and completed residencies in internal medicine and dermatology at Mount Sinai.

Dr. John Y. M. Koo
Dr. Koo is a professor of Clinical Dermatology at the University of California at San Francisco (UCSF) School of Medicine and is Director of the Psoriasis, Phototherapy, and Skin Treatment Clinic. He is a graduate of Harvard Medical School and a Harvard National Scholar. Dr. Koo completed an internship and residency in psychiatry at the University of California, Los Angeles.

Dr. Alice Gottlieb
Dr. Gottlieb is a professor of Dermatology at Tufts University School of Medicine, Chair of Dermatology and Dermatologist-in-Chief of the hospital at Tufts Medical Center. She is an internationally recognized leader in the fields of psoriasis and psoriatic arthritis and is currently a member of the Board of Directors of the American Academy of Dermatology. Dr. Gottlieb received her medical degree from Cornell University and a Ph.D. in Immunology from the Rockefeller University.

Dr. Craig Leonardi
Dr. Leonardi is a Clinical Professor of Dermatology at St. Louis University Medical School in St. Louis, Missouri. He is a founding member and current Treasurer of the International Psoriasis Council. Dr. Leonardi has been involved in more than 190 clinical trials and has published more than 200 original articles. He graduated from the University of Miami School of Medicine and completed residencies in pediatrics and dermatology at the University of Miami/Jackson Memorial Hospital.

Dr. David Pariser
Dr. Pariser is a professor at the Eastern Virginia Medical School Department of Dermatology. He is Past President of the American Academy of Dermatology and is currently on the Board of Directors. He is regularly involved in clinical research and is on the forefront of pharmaceutical development in the field of Psoriasis. Dr. Pariser is a graduate of the Medical College of Virginia, and received his dermatology training at the University of Miami/Jackson Memorial Hospital. He is also Board Certified in dermatology.

About Convoy Therapeutics
Convoy Therapeutics is a late stage dermatology company using its proprietary platform of peptides, including the SPACETM peptide, to enable or enhance delivery and retention of actives in the skin. The basic technology was originally discovered by Professor Samir Mitragotri at the University of California at Santa Barbara and includes a variety of peptides and formulation techniques, which when combined, provide exceptional enhancement of macromolecule penetration into the skin.

For further information on Convoy Therapeutics please visit http://www.convoytx.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300954.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convoy Therapeutics Granted Patent for Proprietary SPACE Technology
2. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
3. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
4. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
5. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
6. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
7. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
8. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
9. PTC Therapeutics Expands Management Team
10. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
11. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):